Januvia (Sitagliptin) Canada
Description
Januvia is a powerful remedy that aims at reducing the concentration of glucose or sugar in human blood, i.e. having strong hypoglycaemic pharmacological action. The preparation's composition includes sitagliptin, the active ingredient and a range of adjuvants - sodium stearyl fumarate, magnesium stearate, microcrystalline cellulose, croscarmellose sodium, calcium hydrogen phosphate. The core component is designed to deactivate DPP-4, the enzyme leading to undesired consequences.
Januvia pharmacological action
The mechanisms that regulates carbohydrate metabolism are characterized by diverse nature. Among others, there are some hormones, such as incretins, released after ingestion. The hormones stimulate the production of insulin and delay the development of glucose in the liver. Such processes take place only in case glucose level is increased, but the presence of hypoglycemia (the term standing for low sugar level) further reduction of glucose is not required and does not occur. Incretins are destroyed by DPP-4 enzyme very quickly. As noted, the active ingredient deactivates the enzyme, thereby preventing degradation of incretins. After oral administration, the drug is rapidly absorbed from the gastrointestinal tract, reaching its maximum concentration after one to four hours. The absolute level of bioavailability of the main component is 87% associated with the blood supply to the 38%, is excreted primarily in the urine, the half-life equals about twelve and a half hours.
Januvia administration
Drug Januvia is admitted as a film-coated tablets for oral administration. It contains 100 milligrams of the active ingredient, typically produced with 14 pills in a blister and two blisters in cardboard packaging. The shelf life equals approximately two years. Januvia drug taken orally regardless of the meal one tablet or one hundred milligrams each 24 hours. In case of renal insufficiency of both stages, moderate and severe (and in patients sufering from renal failure of final stage that requires hemodialysis) should take 50 + 25 milligrams of the drug per day, respectively.
Januvia indications for use
Januvia drug is recommended for admission in a variety of cases. In monotherapy the preparation is prescribed as an adjunct to diet to bear physical exercise and during the diabetes of second tyep to increase control over blood glucose. In combinative therapy of diabetes (second type) the medication is typically prescribed in conjunction with PPARdrugs (thiazolidinediones or other) or metformin in order to enhance glycemic control if the above method alone does not provide to the necessary results.
Januvia contraindications
Januvia treatment must be avoided in the patients with diabetes (type one) ; in those suffering from diabetic ketoacidosis; in case of hypersensitivity to any medication components; in childhood and adolescence to eighteen years (though, no clinical trials have been organised); in women during pregnancy and breastfeeding periods. Precautions are the following: the individuals with renal insufficiency of both severe and moderate cases and those with renal insufficiency characterised by terminal stage should be prescribed the remedy with caution.